Objective: To determine the minimum inhibitory concentration of meronem and imipenem on gram-negative bacterial pathogens isolated from clinical specimens in No.108 Hospitals. Method: The study described the cross. 102 strains of Gram-negative pathogens isolated from clinical specimens. Identified by the identifier bar API (BioMerieux) and the Phoenix (BD). Susceptibility testing routinely checked by diffusion technique (Kirby-Bauer), MIC of Meropenem and Imipenem war by E-test technique. Results: From 05/2009 to 09/2009, 102 strains of Gramnegative bacteria were examined with MIC, MIC50 MIC90 of Meropenem and Imipenem, and the findings were as follows: With E.coli MIC50 of Meropenem0.094 mg/L, Imipenem 0.38 mg/L. MIC90 of Meropenem 1 mg/L and the Imipenem 2 mg/L, with Klebsiella spp. MIC50 of Meropenem 0.094 mg/L of Imipenem 0.38 mg/L. MIC90 of Meropenem 0.38 mg/L and the Imipenem 1.5 mg/L, with the P. aeruginosa MIC50 of Meropenem0.75 mg/L Imipenem 1.5 mg/L. MIC90 of Meropenem 4 mg/L and of Imipenem 4 mg/L, the distribution MIC of Meropenem is always lower than that of Imipenem in all strains studied. Conclusion: The distribution MIC of Meropenem is always lower than the MIC of Imipenem
Imipenem's MIC tends to concentrate near the fracture susceptibility.